JP2020533962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533962A5 JP2020533962A5 JP2020506978A JP2020506978A JP2020533962A5 JP 2020533962 A5 JP2020533962 A5 JP 2020533962A5 JP 2020506978 A JP2020506978 A JP 2020506978A JP 2020506978 A JP2020506978 A JP 2020506978A JP 2020533962 A5 JP2020533962 A5 JP 2020533962A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- amino acid
- acid sequence
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 111
- 108091033319 polynucleotide Proteins 0.000 claims description 81
- 239000002157 polynucleotide Substances 0.000 claims description 81
- 102000040430 polynucleotide Human genes 0.000 claims description 81
- 102000023732 binding proteins Human genes 0.000 claims description 64
- 108091008324 binding proteins Proteins 0.000 claims description 64
- 108091008874 T cell receptors Proteins 0.000 claims description 60
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 60
- 150000001413 amino acids Chemical class 0.000 claims description 56
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 210000000987 immune system Anatomy 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 13
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 108700026220 vif Genes Proteins 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 230000003463 hyperproliferative effect Effects 0.000 claims description 8
- 102200055464 rs113488022 Human genes 0.000 claims description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 7
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 210000004443 dendritic cell Anatomy 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- 210000000822 natural killer cell Anatomy 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 5
- 230000002759 chromosomal effect Effects 0.000 claims description 5
- 239000012636 effector Substances 0.000 claims description 5
- 238000003209 gene knockout Methods 0.000 claims description 5
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 5
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 4
- 208000015799 differentiated thyroid carcinoma Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- GFZFAQOKWZGMQL-UHFFFAOYSA-N 3-[3,5-bis(trifluoromethyl)phenyl]-3-oxopropanenitrile Chemical compound FC(F)(F)C1=CC(C(=O)CC#N)=CC(C(F)(F)F)=C1 GFZFAQOKWZGMQL-UHFFFAOYSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 101150091887 Ctla4 gene Proteins 0.000 claims description 2
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 claims description 2
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 claims description 2
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 2
- 108010065026 HLA-DQB1 antigen Proteins 0.000 claims description 2
- 102210010944 HLA-DQB1*0302 Human genes 0.000 claims description 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims description 2
- 201000007687 Langerhans cell sarcoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 210000004500 stellate cell Anatomy 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 68
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 230000003394 haemopoietic effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 210000003515 double negative t cell Anatomy 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- 108090000695 Cytokines Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 2
- OTJHLDXXJHAZTN-BYPYZUCNSA-N S-(2-boronoethyl)-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCCB(O)O OTJHLDXXJHAZTN-BYPYZUCNSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001400 myeloablative effect Effects 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- ZADWXFSZEAPBJS-JTQLQIEISA-N 1-methyl-L-tryptophan Chemical compound C1=CC=C2N(C)C=C(C[C@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-JTQLQIEISA-N 0.000 description 1
- RCIVCQNKPBGVPA-UHFFFAOYSA-N 6-boronohexanoic acid Chemical compound OB(O)CCCCCC(O)=O RCIVCQNKPBGVPA-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 102100031351 Galectin-9 Human genes 0.000 description 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
- 102000002698 KIR Receptors Human genes 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- FQWRAVYMZULPNK-BYPYZUCNSA-N N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)NO FQWRAVYMZULPNK-BYPYZUCNSA-N 0.000 description 1
- 101150065403 NECTIN2 gene Proteins 0.000 description 1
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 1
- 102100035488 Nectin-2 Human genes 0.000 description 1
- KOBHCUDVWOTEKO-VKHMYHEASA-N Nomega-hydroxy-nor-l-arginine Chemical compound OC(=O)[C@@H](N)CCNC(=N)NO KOBHCUDVWOTEKO-VKHMYHEASA-N 0.000 description 1
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 108010091268 alpha-Macroglobulins Proteins 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229940056913 eftilagimod alfa Drugs 0.000 description 1
- 229950006370 epacadostat Drugs 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 108010004131 poly(beta-D-mannuronate) lyase Proteins 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940126625 tavolimab Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023090881A JP2023105045A (ja) | 2017-08-11 | 2023-06-01 | Ｂｒａｆ特異的ｔｃｒおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762544695P | 2017-08-11 | 2017-08-11 | |
| US62/544,695 | 2017-08-11 | ||
| PCT/US2018/046350 WO2019033057A1 (en) | 2017-08-11 | 2018-08-10 | SPECIFIC BRAF TCR AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023090881A Division JP2023105045A (ja) | 2017-08-11 | 2023-06-01 | Ｂｒａｆ特異的ｔｃｒおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533962A JP2020533962A (ja) | 2020-11-26 |
| JP2020533962A5 true JP2020533962A5 (enExample) | 2021-09-24 |
Family
ID=65272504
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020506978A Pending JP2020533962A (ja) | 2017-08-11 | 2018-08-10 | Ｂｒａｆ特異的ｔｃｒおよびその使用 |
| JP2023090881A Pending JP2023105045A (ja) | 2017-08-11 | 2023-06-01 | Ｂｒａｆ特異的ｔｃｒおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023090881A Pending JP2023105045A (ja) | 2017-08-11 | 2023-06-01 | Ｂｒａｆ特異的ｔｃｒおよびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12398191B2 (enExample) |
| EP (1) | EP3665191A4 (enExample) |
| JP (2) | JP2020533962A (enExample) |
| KR (1) | KR20200035104A (enExample) |
| CN (1) | CN111212848A (enExample) |
| AU (1) | AU2018314242A1 (enExample) |
| CA (1) | CA3070855A1 (enExample) |
| MX (1) | MX2020001287A (enExample) |
| WO (1) | WO2019033057A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109679917B (zh) * | 2018-09-30 | 2020-09-25 | 北京鼎成肽源生物技术有限公司 | 一种lrfft2细胞 |
| GB201819540D0 (en) * | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| CN111057690A (zh) * | 2019-12-23 | 2020-04-24 | 维塔恩(广州)医药有限公司 | 肿瘤相关基因braf突变相关抗原短肽及其应用 |
| WO2021247908A1 (en) * | 2020-06-03 | 2021-12-09 | Bionecure Therapeutics, Inc. | Trophoblast cell-surface antigen-2 (trop-2) antibodies |
| WO2021243695A1 (en) * | 2020-06-05 | 2021-12-09 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Tcr-t cell therapy targeting epstein-barr virus |
| WO2024097637A1 (en) * | 2022-10-31 | 2024-05-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla-a3-restricted t cell receptors against braf with v600e mutation |
| KR20250093237A (ko) * | 2023-12-14 | 2025-06-24 | (주)지아이이노베이션 | Cd80 단백질과 il-2 단백질을 포함하는 융합단백질 및 키메라 항원 수용체를 발현하는 t 세포를 포함하는 암의 예방 또는 치료용 조성물 |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA15704A (en) | 1882-10-26 | Jordan, Robert G. | Improvements on furniture castors | |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US8206965B2 (en) | 2002-03-15 | 2012-06-26 | Cellectis S.A. | Hybrid and single chain meganucleases and use thereof |
| WO2004067753A2 (en) | 2003-01-28 | 2004-08-12 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| WO2007002811A2 (en) | 2005-06-29 | 2007-01-04 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating melanoma |
| CA2626262C (en) | 2005-10-18 | 2015-09-08 | Homme W. Hellinga | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |
| KR101319499B1 (ko) | 2008-02-22 | 2013-10-17 | 엘지디스플레이 주식회사 | 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법 |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| JP6208580B2 (ja) | 2010-05-17 | 2017-10-04 | サンガモ セラピューティクス， インコーポレイテッド | 新規のｄｎａ結合タンパク質及びその使用 |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| WO2013170066A1 (en) * | 2012-05-09 | 2013-11-14 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Peptides for the treatment of cancer |
| PL4289948T3 (pl) | 2012-05-25 | 2025-06-02 | The Regents Of The University Of California | Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji |
| KR102264290B1 (ko) | 2012-08-20 | 2021-06-10 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법을 위한 방법 및 조성물 |
| PL2784162T3 (pl) | 2012-12-12 | 2016-01-29 | Broad Inst Inc | Opracowanie systemów, metod oraz zoptymalizowanych kompozycji przewodnikowych do manipulacji sekwencyjnej |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014100439A2 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| WO2015071474A2 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| SG11201605046YA (en) * | 2013-12-20 | 2016-07-28 | Hutchinson Fred Cancer Res | Tagged chimeric effector molecules and receptors thereof |
| US10202640B2 (en) * | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
| US10059768B2 (en) | 2014-09-12 | 2018-08-28 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| KR102357004B1 (ko) * | 2014-10-27 | 2022-01-27 | 프레드 헛친슨 켄서 리서치 센터 | 입양 세포 면역요법의 효능을 강화하기 위한 조성물 및 방법 |
| US10227408B2 (en) | 2015-02-19 | 2019-03-12 | Compugen Ltd. | Anti-PVRIG antibodies and methods of use |
| EP3277294B1 (en) | 2015-04-01 | 2024-05-15 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| EP3384294B1 (en) | 2015-12-04 | 2021-10-13 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
| US11026969B2 (en) * | 2015-12-23 | 2021-06-08 | Fred Hutchinson Cancer Research Center | High affinity T cell receptors and uses thereof |
-
2018
- 2018-08-10 JP JP2020506978A patent/JP2020533962A/ja active Pending
- 2018-08-10 KR KR1020207006074A patent/KR20200035104A/ko not_active Ceased
- 2018-08-10 WO PCT/US2018/046350 patent/WO2019033057A1/en not_active Ceased
- 2018-08-10 EP EP18843181.1A patent/EP3665191A4/en active Pending
- 2018-08-10 CN CN201880066631.XA patent/CN111212848A/zh active Pending
- 2018-08-10 US US16/638,339 patent/US12398191B2/en active Active
- 2018-08-10 MX MX2020001287A patent/MX2020001287A/es unknown
- 2018-08-10 AU AU2018314242A patent/AU2018314242A1/en not_active Abandoned
- 2018-08-10 CA CA3070855A patent/CA3070855A1/en active Pending
-
2023
- 2023-06-01 JP JP2023090881A patent/JP2023105045A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533962A5 (enExample) | ||
| Rui et al. | Cancer immunotherapies: advances and bottlenecks | |
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| Xue et al. | Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy | |
| Souza-Fonseca-Guimaraes et al. | The emergence of natural killer cells as a major target in cancer immunotherapy | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP7005346B2 (ja) | 養子細胞免疫療法の有効性を増強させるための組成物および方法 | |
| JP2020509767A5 (enExample) | ||
| KR102763121B1 (ko) | 치료적 면역 세포의 효능의 향상 방법 | |
| Fong et al. | Anti–cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment | |
| JP2023093469A (ja) | 抗ｃｄ１６ａ抗体のサイトカインとの組み合わせ | |
| Olson et al. | Adoptive cell therapy for nonhematologic solid tumors | |
| CN112639102A (zh) | 抗间皮素嵌合抗原受体(car)构建体及其用途 | |
| Marotte et al. | Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes | |
| Heyman et al. | New developments in immunotherapy for lymphoma | |
| US20230226181A1 (en) | GENETIC ENGINEERING OF gamma delta T CELLS FOR IMMUNOTHERAPY | |
| CN113891718A (zh) | 人工免疫监视嵌合抗原受体(ai-car)及其表达细胞 | |
| Cortes-Hernandez et al. | Chimeric antigen receptor (CAR) T cell therapy for cancer. Challenges and opportunities: An overview | |
| Mungalov et al. | Engaging T cells for cleanup | |
| WO2022056304A1 (en) | Compositions and methods for tcr reprogramming using nectin-4 specific fusion proteins | |
| Zhao et al. | Current status and future perspective of natural killer cell therapy for cancer | |
| WO2023108150A1 (en) | Methods for cancer immunotherapy | |
| JPWO2019157524A5 (enExample) | ||
| CN120882754A (zh) | 用淋巴毒素β受体激动剂治疗癌症的方法 | |
| US20240148867A1 (en) | Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine |